Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Therapeutic potential of NRF2 activating drug RTA-408 in suppressing T cell effector responses and inflammatory bowel disease

The Journal of Immunology(2025)10.1093/jimmun/vkaf117Source: DataRank Database

Therapeutic potential of NRF2 activating drug RTA-408 in suppressing T cell effector responses and inflammatory bowel disease is a research paper published in The Journal of Immunology (2025). On theSindex it has a DataRank of 0. It has been cited 4 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access4 citations

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (15 grants)Impact (FWCI 1.59)OA: greenTopics (52)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (6)

Aprajita Tripathi,Rachel Griffard ORCID,Nanda Kumar Yellapu ORCID,Poojaben Dhorajiya,Kalyani Pyaram ORCID

Live enrichment

PubMed:40570091 PMC:PMC12394995 OpenAlex:https://openalex.org/W4411686619

Kansas Idea Network of Biomedical Research Excellence

Grant: P20 GM103418

Kansas Institute for Precision Medicine COBRE

Grant: P20 GM130423

National Cancer Institute

Grant: P30 CA168524

NIH

Grant: U54 HD 090216

NIA NIH HHS

Grant: P30 AG072973

Kansas Cancer Center's Biospecimen Core Facility

NIGMS

NIH HHS

KIDDRC

University of Kansas Cancer Center

NIGMS

KIDDRC

NIH HHS

Kansas Cancer Center's Biospecimen Core Facility

University of Kansas Cancer Center

FWCI

1.59

Citation Percentile

0.8%

Citation Trend

2025

2026

greenLicense: https://academic.oup.com/pages/standard-publication-reuse-rights

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC12394995/

publisherhttps://academic.oup.com/jimmunol/article-pdf/214/8/1951/63502922/vkaf117.pdf

journalhttps://doi.org/10.1093/jimmun/vkaf117

repositoryhttps://pubmed.ncbi.nlm.nih.gov/40570091

Fields of Study

Genomics, phytochemicals, and oxidative stressImmune Cell Function and InteractionIL-33, ST2, and ILC PathwaysNF-E2-Related Factor 2AnimalsInflammatory Bowel DiseasesMiceHumansLymphocyte ActivationMice, Inbred C57BLOleanolic AcidT-Lymphocytes, RegulatoryMice, KnockoutCell ProliferationColitisMale

MeSH Terms

AnimalsColitisHumansLymphocyte ActivationMaleMice, Inbred C57BLOleanolic AcidInflammatory Bowel DiseasesMice, KnockoutCell ProliferationT-Lymphocytes, RegulatoryNF-E2-Related Factor 2Mice

Keywords

Inflammatory bowel diseaseT cellCytotoxic T cellCancer researchInflammationFOXP3CytokineEx vivoPharmacologyImmunologyBiologyChemistryMedicineImmune systemIn vitroInternal medicineDiseaseBiochemistryCytokinesAntioxidationUlcerative colitisImmunometabolismNrf2 Activating Drugs

Sustainable Development Goals

SDG 0: Good health and well-being

Therapeutic potential of NRF2 activating drug RTA-408 in suppressing T cell effector responses and inflammatory bowel disease

FAIR Checklist

Authors (6)

Funding (15 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)